| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing–remitting multiple sclerosis
|
Martin, Roland
|
|
2012
|
142 |
1 |
p. 9-14
6 p.
|
article
|
| 2 |
Cladribine as a therapeutic option in multiple sclerosis
|
Warnke, Clemens
|
|
2012
|
142 |
1 |
p. 68-75
8 p.
|
article
|
| 3 |
Dalfampridine in multiple sclerosis: From symptomatic treatment to immunomodulation
|
Espejo, Carmen
|
|
2012
|
142 |
1 |
p. 84-92
9 p.
|
article
|
| 4 |
DNA-based vaccines for multiple sclerosis: Current status and future directions
|
Fissolo, Nicolas
|
|
2012
|
142 |
1 |
p. 76-83
8 p.
|
article
|
| 5 |
Editorial Board
|
|
|
2012
|
142 |
1 |
p. IFC-
1 p.
|
article
|
| 6 |
Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy
|
Ingwersen, Jens
|
|
2012
|
142 |
1 |
p. 15-24
10 p.
|
article
|
| 7 |
Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action
|
Gold, R.
|
|
2012
|
142 |
1 |
p. 44-48
5 p.
|
article
|
| 8 |
Immune mechanisms of new therapeutic strategies in MS — Teriflunomide
|
Claussen, Malte C.
|
|
2012
|
142 |
1 |
p. 49-56
8 p.
|
article
|
| 9 |
Immune mechanisms of new therapeutic strategies in multiple sclerosis—A focus on alemtuzumab
|
Klotz, Luisa
|
|
2012
|
142 |
1 |
p. 25-30
6 p.
|
article
|
| 10 |
Immunopathogenesis of multiple sclerosis
|
Comabella, Manuel
|
|
2012
|
142 |
1 |
p. 2-8
7 p.
|
article
|
| 11 |
Laquinimod in multiple sclerosis
|
Giacomini, Paul S.
|
|
2012
|
142 |
1 |
p. 38-43
6 p.
|
article
|
| 12 |
Neuroprotective agents: Cannabinoids
|
Sánchez, A.J.
|
|
2012
|
142 |
1 |
p. 57-67
11 p.
|
article
|
| 13 |
Reviewer Acknowledgement
|
|
|
2012
|
142 |
1 |
p. 93-94
2 p.
|
article
|
| 14 |
Therapeutic strategies in multiple sclerosis
|
Comabella, Manuel
|
|
2012
|
142 |
1 |
p. 1-
1 p.
|
article
|
| 15 |
Treatment of multiple sclerosis with Anti-CD20 antibodies
|
Barun, Barbara
|
|
2012
|
142 |
1 |
p. 31-37
7 p.
|
article
|
Journal description